Virpax Stock Analysis

VRPX -  USA Stock  

USD 4.32  0.27  6.67%

Virpax Pharmaceuticals price slide over the last few months may raise some interest from investors as it is trading at a share price of 4.32 on very low momentum in trading volume. The company executives were not very successful in positioning the company resources to exploit market volatility in May. However, diversifying your holdings with Virpax Pharmaceuticals or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.93. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Virpax Pharmaceuticals partners.
Also, please take a look at World Market Map.

Search Stock Analysis 

The Virpax Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Virpax Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Virpax stock analysis module also helps to analyze the Virpax Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Virpax Stock Analysis Notes

The company had not issued any dividends in recent years. Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people. For more information please call the company at 484 880 4588 or visit

Virpax Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Virpax Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Virpax Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Virpax Pharmaceuticals generates negative expected return over the last 90 days
Virpax Pharmaceuticals has high historical volatility and very poor performance
The company currently holds 1.57 M in liabilities. Virpax Pharmaceuticals has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
Net Loss for the year was (4.33 M).
Virpax Pharmaceuticals currently holds about 256.5 K in cash with (1.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08.

Virpax Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Virpax Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Virpax Pharmaceuticals backward and forwards among themselves. Virpax Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Virpax Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Sabby Management LlcCommon Shares200 K942 K
Zeke Capital Advisors LlcCommon Shares45 K212 K
Hn Saltoro Capital LpCommon Shares27 K127 K
Ubs Group AgCommon SharesK14 K
Advisor Group Holdings IncCommon Shares89.00.0
Proequities IncCommon Shares0.00.0
Note, although Virpax Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Virpax Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 27.5 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Virpax Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Virpax Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

Virpax Pharmaceuticals management efficiency ratios could be used to measure how well virpax pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 17th of June 2021, Virpax Pharmaceuticals has the Coefficient Of Variation of 3384.3, risk adjusted performance of 0.0275, and Semi Deviation of 5.27. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Virpax Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Virpax Pharmaceuticals, which can be compared to its competition. Please validate Virpax Pharmaceuticals value at risk, as well as the relationship between the semi variance and kurtosis to decide if Virpax Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 4.32 per share. Given that Virpax Pharmaceuticals has jensen alpha of 0.2666, we advise you to double-check Virpax Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.

Virpax Pharmaceuticals Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Virpax Pharmaceuticals more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Virpax Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Virpax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Virpax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Virpax Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Virpax Pharmaceuticals Technical and Predictive Indicators

Virpax Pharmaceuticals Forecast Models

Virpax Pharmaceuticals time-series forecasting models is one of many Virpax Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Virpax Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Virpax Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Virpax Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Virpax shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Virpax Pharmaceuticals. By using and applying Virpax Stock analysis, traders can create a robust methodology for identifying Virpax entry and exit points for their positions.
Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Virpax Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Probability Of Bankruptcy Now


Probability Of Bankruptcy

Get analysis of equity chance of financial distress in the next 2 years
All  Next Launch Module
Also, please take a look at World Market Map. Note that the Virpax Pharmaceuticals information on this page should be used as a complementary analysis to other Virpax Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Virpax Pharmaceuticals Stock analysis

When running Virpax Pharmaceuticals stock analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' stock examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
The market value of Virpax Pharmaceuticals is measured differently than its book value, which is the value of Virpax that is recorded on the company's balance sheet. Investors also form their own opinion of Virpax Pharmaceuticals stock's value that differs from its market value or its book value, called intrinsic value, which is Virpax Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Virpax Pharmaceuticals' market value can be influenced by many factors that don't directly affect Virpax Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Virpax Pharmaceuticals' stock value and its price as these two are different measures arrived at by different means. Investors typically determine Virpax Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Virpax Pharmaceuticals' stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.